Drugs / KLN-1010
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07075185 | Jul 2025 → Mar 2027 expected | blood coagulation disease, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal paraproteinemia disease +2 | Kelonia Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KLN-1010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07075185 ↗ |